E Fund S&P Health Care Index Fund(LOF)(CNY)-A

Almac Group and others win 2025 Visionary Growth Leadership Best Practices Award

CVS Health expects revenue of at least $40 billion in 2025

CVS Health expects total revenue to reach at least 400 billion dollars in 2026

CVS Health Raises 2025 Profit Forecast and Predicts 2026 Earnings Beat

First Trust Advisors LP reduced holdings of Boston Scientific

California Public Employees' Retirement System Increases Holdings in Intuitive Surgical

Humana's stock price rises as Jefferies upgrades rating to 'buy'

CVS HEALTH CREATED OVER $474 BILLION OF ECONOMIC IMPACT IN 2024

HCA Healthcare donates $4.8 million to Pepperdine University's Nursing School

SCS Capital Management LLC Increases Holdings in HCA Healthcare

Norwegian Bank Acquired 460,024 Shares of Universal Health in Q2

Amundi Reduced Holdings in Intuitive Surgical

Cencora Expanding Logistics Capabilities Through Investments

Humana Discusses Potential Pharmacy Partnership with Mark Cuban

CVS Health Corporation Plans to Simplify Healthcare with AI

JPMorgan Raises Target Price on Cencora

Wells Fargo Analyst Updates CVS Health Target Price and Rating

Shanghai Mayor Meets Boston Scientific CEO

Invesco Increases Boston Scientific Shares

Intuitive Surgical VP Myriam Curet Sells Shares

Health care stocks declined, with NYSE Health Care Index down 0.4%. Pfizer signed a deal with YaoPharma for weight management drug YP05002, shares down 0.9%. CVS Health raised its full-year outlook, shares up 2.9%. Teleflex sold units for $2.03 billion, shares up 11%.

- Health care stocks experienced a decline, with the NYSE Health Care Index down 0.4% and the State Street Health Care Select Sector SPDR ETF decreasing 0.5%.  
- Pfizer announced a global collaboration with YaoPharma for chronic weight management, resulting in a 0.9% drop in its shares, while CVS Health raised its full-year outlook, leading to a 2.9% increase in its stock.  
- Teleflex agreed to sell several units for $2.03 billion in cash, causing its shares to rise over 11%.

fidelity

Pfizer

Teleflex

CVS Health

Sector Update: Health Care Stocks Lower in Afternoon Trading

CVS Health shares rose ~3% as analysts welcomed its long-term guidance despite underwhelming 2026 revenue projections. The company increased its 2025 financial guidance, projecting at least $400B in revenue and $6.60-$6.70 EPS. Analysts praised CVS's mid-teens EPS CAGR through 2028, highlighting earnings recovery potential. CVS unveiled a new consumer engagement platform to integrate its business entities. Analysts from TD Cowen, Evercore ISI, and Leerink Partners gave positive ratings, while Seeking Alpha's Mike Zaccardi raised his price target to $93 per share.

CVS Health rises as analysts welcome long-term guidance (update)

Jim Cramer praises CVS Health's turnaround under CEO DaviCVSd Joyner, highlighting its shift from retail to healthcare services. CVS raised its profit guidance for 2026, boosting its stock by 80% since early 2025. Cramer views CVS as a top healthcare company, with Wall Street agreeing, rating it "overweight" with a target of $93. CVS's earnings are expected to exceed forecasts, and technical indicators suggest continued stock growth into 2026.

Invezz

Jim Cramer says CVS stock may be the only first-class healthcare name we have

Stocks remained largely unchanged as investors awaited the Federal Reserve's final policy decision of the year. The S&P 500 was flat, the Dow rose slightly, and the Nasdaq fell due to tech sector weakness. Markets anticipate a 25 basis point rate cut, with an 89% probability. CVS shares rose on strong profit outlook, while tech stocks showed mixed performance. Investors seek clarity on future rate cuts, with muted expectations for January and March. Dovish signals from the Fed are hoped for.

S&P 500, Nasdaq open flat ahead of the Fed decision

CVS Health has raised its 2025 revenue guidance to $400 billion, surpassing previous estimates and FactSet's forecast. The company also increased its adjusted EPS guidance to $6.60-$6.70. CVS attributes its strong performance to Aetna's target margins and growth in its pharmacy-benefit business. CVS stock has risen 78% this year, outperforming other health insurers. The company expects 2026 revenue of $400 billion and adjusted EPS of $7-$7.20.

Dow Jones

CVS stock rallies as health giant signals stronger-than-expected results in 2025

ISRG

Frost & Sullivan Institute announced the recipients of the 2025 Visionary Growth Leadership Best Practices Recognition, honoring organizations for mission-driven innovation and sustainable progress. Awardees include Almac Group, Intuitive Surgical, and Alphabet Inc., among others. The evaluation process involves a comprehensive assessment of long-term growth, innovation capability, and societal impact. The Institute aims to highlight contributions to global well-being and promote sustainable development.

prnewswire

Intuitive Surgical

Alphabet

Alphabet - C

10:05 ET
			
			
				The Frost & Sullivan Institute Honors Global Organizations Advancing Sustainable Progress with the 2025 Visionary Growth Leadership Best Practices Recognition

Home Depot anticipates higher sales with increased housing activity. CVS Health raises profit guidance for 2026. Trump's Nvidia deal impacts U.S.-China tech relations. Campbell's profits fall; acquires stake in La Regina. EU investigates Google's AI content use. Anthropic and Accenture target AI business clients. Ford and Renault collaborate on EVs in Europe. BMW appoints Milan Nedeljkovic as new chief. Sam Altman focuses on ChatGPT's popularity. PepsiCo cuts costs in deal with Elliott. Ares replaces Kellanova in S&P 500. BHP sells power stake to BlackRock. CoreWeave issues $2.25 billion in debt.

MorningStar

Home Depot

Dow Jones Top Company Headlines at 9 AM ET: Home Depot Expects Higher Sales if Housing Activity Grows | CVS ...

SVB Wealth LLC invested $1.36 million in CVS Health Corporation during Q2. Analysts have issued positive ratings, with Jefferies Financial Group, TD Cowen, and Wolfe Research increasing their target prices. CVS Health reported strong earnings, beating estimates with $1.60 EPS and $102.87 billion revenue. The company announced a quarterly dividend of $0.665, yielding 3.5%. CVS Health's stock performance and analyst ratings suggest potential growth.

Market Beat

SVB Wealth LLC Makes New $1.36 Million Investment in CVS Health Corporation $CVS

Wall Street is set for a muted open as investors await the Federal Reserve's rate decision. Nvidia shares fluctuate due to export news to China, while a bidding war over Warner Bros heats up. The Fed's policy meeting is in focus, with traders expecting a rate cut amid inflation concerns. Home Depot and CVS Health show contrasting stock movements.

US STOCKS-Wall St poised for muted open as Fed rate cut decision nears

HCA Healthcare Inc. has appointed Virginia Tenpenny as vice president of community engagement, effective January 12, 2026, succeeding Joanne Pulles. Tenpenny has over two decades of experience in corporate community impact, previously serving at NationSwell and Starbucks.

Reuters

HCA Healthcare

HCA Healthcare Appoints Virginia Tenpenny as Vice President of Community Engagement

Cigna (CI.US) has recently been extremely sluggish, with mainstream funds in the insurance sector continuously withdrawing. The market is in a sideways trend, and there is a heightened sentiment in the community discussing "how long will the sideways consolidation last, and is it time for a rotation opportunity in the sector?"

Technical Forecast

Cigna

Morning Trend | Cigna is consolidating at the bottom, is a sector rotation opportunity coming?

Cigna (CI.US) has seen a slight pullback after a surge in recent trading days, with increasing signals of unusual activity from major players. The community is focused on the question, 'Is a second rally just around the corner?' The company is benefiting from favorable policies and a recovery in health insurance, with institutional long-term funds significantly increasing their allocations. On the technical side, there is a low-level rebound on the daily chart, with a mildly bullish moving average structure, and active funds frequently attempt to push prices higher during intraday trading. If short-term trading volume becomes active again and breaks through the resistance zone of 260-265, it could lead to a new round of short-term opportunities. Caution is advised for false breakouts followed by rapid declines, but if major players continue to control the market, there is potential for upward movement worth speculating on in the short term. It is recommended to closely track intraday fluctuations and sector correlations to seize opportunities during trading sessions

Morning Trend | Cigna tests upward, is a second capital breakthrough coming?

First Trust Advisors LP reduced its stake in Boston Scientific Corporation by 30.5% in Q2, selling 188,265 shares. Other institutional investors like Vanguard and Geode Capital increased their holdings. Insider sales included Director Ellen M. Zane and EVP Joseph Michael Fitzgerald. Analysts maintain a 'Buy' rating with a consensus target price of $123.77. Boston Scientific's stock opened at $93.66, with a market cap of $138.84 billion.